MedPath

Prediction of Early Recovery of Liver Function After LDLT in Children: An Ambispective Cohort Study

Completed
Conditions
Other End-stage Liver Diseases in Children
Liver and Biliary Tract Disorders in Duration of Pregnancy
Registration Number
NCT06045949
Lead Sponsor
Huiwu Xing
Brief Summary

The investigators included children with living donor liver transplantation (LDLT) from January 1, 2018 to July 31, 2022 as a retrospective cohort, and the group from August 1, 2022 to June 30, 2023 as a prospective cohort. The investigators collected the demographic and clinicopathological data of donors and recipients, and determined the risk factors of early postoperative delayed recovery of hepatic function (DRHF) by univariate and multivariate Logical regression analyses.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
230
Inclusion Criteria
  1. children with the indication of LDLT [cholestatic liver disease (such as BA), metabolic liver disease (such as Wilson's disease and Ornithine transcarbamylase deficiency), acute liver failure (such as drug induced), neoplastic disease (such as hepatoblastoma), vascular disease (such as cavernous transformation of portal vein and congenital absence of portal vein), re-transplantation and others];
  2. the relatives of the children voluntarily donated part of the liver which met the requirements of LDLT.
Exclusion Criteria
  1. recipients with contraindications of LDLT (such as coagulation dysfunction, acute infection, cardiopulmonary failure);
  2. failure to complete LDLT due to various reasons (such as death during or within 3 days after operation);
  3. recipients or donors with incomplete necessary data.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
DRHF30 days after LDLT in children

Investigators collected liver function data of children after LDLT. Delayed recovery of hepatic function (DRHF) is characterized by the increase of PT-INR combined with hyperbilirubinemia on or after postoperative day 5.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Children's Hospital of Chongqing Medical University

🇨🇳

Chongqing, Chongqing, China

© Copyright 2025. All Rights Reserved by MedPath